Optimal Dosing of Acetylsalicylic Acid

Public Health Agency of Canada. Leading causes of death and hospitalization in Canada. Sept. 22, 2000. Available: www.phac-aspc.gc.ca/publicat/lcd-pcd97/mrt_mf_e.html#pertab2 (accessed Nov. 13, 2006)

Heart and Stroke Foundation. Incidence of cardiovascular disease. Ottawa: Heart and Stroke Foundation; 2002. Available: ww2.heartandstroke.ca/Page.asp?PageID=33&ArticleID=1077&Src=news&From=SubCategory (accessed Nov 10, 2006)

Berger JS Roncaglioni MC Avanzini F Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295 (3): 306–13

Johnson ES Lanes SF Wentworth CE 3rd A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159 (11): 1248–53

Hennekens CH Sechenova O Hollar D Serebruany VL. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther 2006; 11 (3): 170–6

Weisman SM Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162 (19): 2197–202

DiPiro JT Talbert RL Yee GC , eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw-Hill; 2005

Bartolucci AA Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006; 98 (6): 746–50

U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136 (2): 157–60

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71–86

Hayden M Pignone M Phillips C Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136 (2): 161–72

Derry S Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321 (7270): 1183–7

McQuaid KR Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119 (8): 624–38

Rodriguez LA Garcia Hernandez-Diaz S de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52 (5): 563–71

Serebruany VL Steinhubl SR Berger PB Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95 (10): 1218–22

Pearson TA Blair SN Daniels SR AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106 (3): 388–91

Smith SC Jr Allen J Blair SN Bonow RO AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113 (19): 2363–72